NCT06723457View on ClinicalTrials.gov

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

February 18, 2027

Study Completion Date

February 18, 2029

Conditions
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Polymorphic Post-Transplant Lymphoproliferative DisorderRefractory B-Cell Non-Hodgkin Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo PET/CT

BIOLOGICAL

Epcoritamab

Given SC

DRUG

Lenalidomide

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

60611

RECRUITING

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT06723457 - Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter